{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:09:52Z","timestamp":1767917392641,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-1037-8","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T15:31:41Z","timestamp":1537457501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD"],"prefix":"10.1186","volume":"19","author":[{"given":"James O.","family":"Burton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicki","family":"Ruddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rukshana","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"issue":"1","key":"1037_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"KDIGO","year":"2017","unstructured":"KDIGO. 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1\u201359.","journal-title":"Kidney Int Suppl"},{"key":"1037_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","volume":"76","author":"Kai-Uwe Eckardt","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1\u2013130. \n                    https:\/\/doi.org\/10.1038\/ki.2009.188\n                    \n                  .","journal-title":"Kidney International"},{"issue":"1","key":"1037_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2014a single-center cohort study. Nephrol Dial Transplant. 2012;27(1):345\u201351.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1037_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2215\/CJN.06040614","volume":"10","author":"KL Naylor","year":"2015","unstructured":"Naylor KL, Garg AX, Zou G, Langsetmo L, Leslie WD, Fraser LA, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol. 2015;10(4):646\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1037_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jbmr.2406","volume":"30","author":"SL West","year":"2015","unstructured":"West SL, Lok CE, Langsetmo L, Cheung AM, Szabo E, Pearce D, et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res. 2015;30(5):913\u20139.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1037_CR6","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2215\/CJN.12871211","volume":"7","author":"RH Yenchek","year":"2012","unstructured":"Yenchek RH, Ix JH, Shlipak MG, Bauer DC, Rianon NJ, Kritchevsky SB, et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol. 2012;7(7):1130\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"1037_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945\u201353.","journal-title":"Kidney Int"},{"issue":"2","key":"1037_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2215\/CJN.09580911","volume":"8","author":"G Garrett","year":"2013","unstructured":"Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ. PTH--a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013;8(2):299\u2013312.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1037_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67(4):559\u201366.","journal-title":"Am J Kidney Dis"},{"key":"1037_CR10","volume-title":"CKD-Mineral and Bone Disorders (CKD-MBD)","author":"UK Renal Association","year":"2015","unstructured":"UK Renal Association. CKD-Mineral and Bone Disorders (CKD-MBD) 2015. Available from: \n                    https:\/\/renal.org\/guidelines"},{"issue":"12","key":"1037_CR11","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2215\/CJN.04260413","volume":"8","author":"GA Block","year":"2013","unstructured":"Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol. 2013;8(12):2132\u201340.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1037_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1681\/ASN.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23(8):1407\u201315.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1037_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ki.2012.403","volume":"83","author":"KM Hill","year":"2013","unstructured":"Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3\u20134 chronic kidney disease. Kidney Int. 2013;83(5):959\u201366.","journal-title":"Kidney Int"},{"key":"1037_CR14","volume-title":"Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia. NICE Guideline (CG157)","author":"National Institute for Health and Care Excellence","year":"2013","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia. NICE Guideline (CG157). 2013."},{"issue":"26","key":"1037_CR15","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"4","key":"1037_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bone.2007.06.014","volume":"41","author":"G Spasovski","year":"2007","unstructured":"Spasovski G, Gelev S, Masin-Spasovska J, Selim G, Sikole A, Vanholder R. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone. 2007;41(4):698\u2013703.","journal-title":"Bone"},{"issue":"8","key":"1037_CR17","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1681\/ASN.2015030268","volume":"27","author":"E Ok","year":"2016","unstructured":"Ok E, Asci G, Bayraktaroglu S, Toz H, Ozkahya M, Yilmaz M, et al. Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis. J Am Soc Nephrol. 2016;27(8):2475\u201386.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1037_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1053\/j.ajkd.2015.03.038","volume":"66","author":"SM Brunelli","year":"2015","unstructured":"Brunelli SM, Sibbel S, Do TP, Cooper K, Bradbury BD. Facility dialysate calcium practices and clinical outcomes among patients receiving hemodialysis: a retrospective observational study. Am J Kidney Dis. 2015;66(4):655\u201365.","journal-title":"Am J Kidney Dis"},{"issue":"40","key":"1037_CR19","doi-asserted-by":"publisher","first-page":"e1694","DOI":"10.1097\/MD.0000000000001694","volume":"94","author":"HW Kim","year":"2015","unstructured":"Kim HW, Kim SH, Kim YO, Jin DC, Song HC, Choi EJ, et al. Impact of dialysate calcium concentration on clinical outcomes in incident hemodialysis patients. Medicine (Baltimore). 2015;94(40):e1694.","journal-title":"Medicine (Baltimore)"},{"issue":"4 Suppl 3","key":"1037_CR20","first-page":"S1","volume":"42","author":"National Kidney Foundation","year":"2003","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1\u2013201.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1037_CR21","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","volume":"62","author":"B Di Iorio","year":"2013","unstructured":"Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1037_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2215\/CJN.03820411","volume":"7","author":"B Di Iorio","year":"2012","unstructured":"Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7(3):487\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9900","key":"1037_CR23","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","volume":"382","author":"SA Jamal","year":"2013","unstructured":"Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268\u201377.","journal-title":"Lancet"},{"issue":"2","key":"1037_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2215\/CJN.06800615","volume":"11","author":"L Patel","year":"2016","unstructured":"Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11(2):232\u201344.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1037_CR25","volume-title":"Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide. Evidence summary (ESNM51)","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide. Evidence summary (ESNM51). 2015."},{"issue":"5","key":"1037_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000157177","volume":"31","author":"A Oksa","year":"2008","unstructured":"Oksa A, Spustova V, Krivosikova Z, Gazdikova K, Fedelesova V, Lajdova I, et al. Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res. 2008;31(5):322\u20139.","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"1037_CR27","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/ASN.2012070719","volume":"24","author":"CD Chue","year":"2013","unstructured":"Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol. 2013;24(5):842\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1037_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47(2):263\u201376.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1037_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5414\/CN107630","volume":"80","author":"MM Lemos","year":"2013","unstructured":"Lemos MM, Watanabe R, Carvalho AB, Jancikic AD, Sanches FM, Christofalo DM, et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clin Nephrol. 2013;80(1):1\u20138.","journal-title":"Clin Nephrol"},{"issue":"6","key":"1037_CR30","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.kint.2016.06.041","volume":"90","author":"P Evenepoel","year":"2016","unstructured":"Evenepoel P, Bover J, Urena TP. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int. 2016;90(6):1184\u201390.","journal-title":"Kidney Int"},{"issue":"7","key":"1037_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674\u201384.","journal-title":"JAMA"},{"issue":"1","key":"1037_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AY Wang","year":"2014","unstructured":"Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, et al. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. J Am Soc Nephrol. 2014;25(1):175\u201386.","journal-title":"J Am Soc Nephrol"},{"key":"1037_CR33","volume-title":"Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Technology appraisal guidance (TA117)","author":"National Institute for Health and Clinical Excellence","year":"2007","unstructured":"National Institute for Health and Clinical Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Technology appraisal guidance (TA117). 2007."},{"issue":"12","key":"1037_CR34","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1111\/j.1600-6143.2008.02423.x","volume":"8","author":"S Akaberi","year":"2008","unstructured":"Akaberi S, Simonsen O, Lindergard B, Nyberg G. Can DXA predict fractures in renal transplant patients? Am J Transplant. 2008;8(12):2647\u201351.","journal-title":"Am J Transplant"},{"issue":"8","key":"1037_CR35","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jbmr.412","volume":"26","author":"AD Baxter-Jones","year":"2011","unstructured":"Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. J Bone Miner Res. 2011;26(8):1729\u201339.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1037_CR36","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1210\/jc.2012-4188","volume":"98","author":"MR Denburg","year":"2013","unstructured":"Denburg MR, Tsampalieros AK, de Boer IH, Shults J, Kalkwarf HJ, Zemel BS, et al. Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidney disease. J Clin Endocrinol Metab. 2013;98(5):1930\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1037_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1053\/j.ajkd.2005.12.039","volume":"47","author":"AK Pieper","year":"2006","unstructured":"Pieper AK, Haffner D, Hoppe B, Dittrich K, Offner G, Bonzel KE, et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis. 2006;47(4):625\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1037_CR38","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1681\/ASN.2004100885","volume":"16","author":"IB Salusky","year":"2005","unstructured":"Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol. 2005;16(8):2501\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1037_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1681\/ASN.2015020152","volume":"27","author":"MR Denburg","year":"2016","unstructured":"Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, et al. Fracture burden and risk factors in childhood CKD: results from the CKiD cohort study. J Am Soc Nephrol. 2016;27(2):543\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"1037_CR40","doi-asserted-by":"publisher","unstructured":"Hahn D, Hodson EM, Craig JC. Interventions for metabolic bone disease in children with chronic kidney disease. Cochrane Database Syst Rev. 2015;(11):Cd008327. \n                    https:\/\/doi.org\/10.1002\/14651858.CD008327.pub2\n                    \n                  .","DOI":"10.1002\/14651858.CD008327.pub2"},{"issue":"1","key":"1037_CR41","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/01.CIR.0000020222.63035.C0","volume":"106","author":"J Oh","year":"2002","unstructured":"Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002;106(1):100\u20135.","journal-title":"Circulation"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1037-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T23:05:12Z","timestamp":1568934312000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1037-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1037-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"29 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors made declarations of interest in line with the policy in the Renal Association Clinical Practice Guidelines Development Manual. Further details can be obtained on request from the Renal Association.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"240"}}